Biotage (BIOT) Q3 2024 earnings summary

Executive summary

• Achieved 12.4% organic revenue growth and 9.1% reported growth year-over-year in Q3 2024, with Americas and EMEA driving gains while China remained a minor contributor due to ongoing headwinds (<5% of group revenue).

• Recurring revenue from services and consumables accounted for 72% of total sales in Q3 and year-to-date, supporting revenue stability.

• Gross margins remained robust at 63% year-to-date and 61.7% in Q3, reflecting operational efficiency despite product/customer mix.

• Adjusted EBITDA for Q3 was SEK 124 million, up 6% year-over-year, and 380 million for the first nine months, up 17%, indicating growing profitability.

• Strong cash generation with adjusted cash flow from operations at SEK 153 million in Q3, representing 124% of adjusted EBITDA.

Financial highlights

• Q3 revenue reached SEK 490 million, up 9% year-over-year (12% organic); year-to-date revenue was SEK 1,474 million, up 21% (7% organic).

• Adjusted EBITDA margin for Q3 was 25.3% (26.1% in Q3 2023); for nine months, 25.8% (26.6%).

• Net cash at quarter-end was SEK 120 million; gross cash was SEK 370 million.

• Earnings per share for Q3 was SEK 0.55; year-to-date was SEK 1.56.

• FX headwinds in Q3 reduced revenue by approximately SEK 50 million (3%).

Outlook and guidance

• Confident in delivering full-year 2024 targets, with strong fundamentals and robust pipeline.

• Management targets average annual double-digit organic revenue growth and upper 20% range profitability (adjusted EBITDA) over three years.

• Additional manufacturing capacity in Isle of Man and Boston to come online in Q4 to support future growth.

• Actions taken to adjust cost base in China due to ongoing market headwinds.

• Margins expected to remain robust, with potential for slight improvement over the full year.